St Barbara (ASX: SBM): Nova Scotia Development Takes Centre Stage as SBM Consolidates Its Gains
St Barbara is reshaping its business through the proposed Simberi sale, stronger cash reserves and a sharper focus on Nova Scotia. The Touquoy restart, 15-Mile project, royalty exposure and potential capital returns now define the company’s next phase.
.webp&w=828&q=75)
Titomic (ASX: TTT): US Air Force Contract Win Follows $16.5 Million Capital Raise
Titomic (ASX: TTT) shares rallied after a US$5 million Air Force contract, following a $16.5 million placement. The advanced manufacturer, still loss-making, is progressing a US redomiciliation while shares test key support with a potential trendline breakout ahead.
EchoIQ (ASX: EIQ) Crisis Decoded: Regulatory Setback, Not Financial Collapse
EchoIQ shares plunged 60% after the FDA issued an NSE notice blocking its heart-failure AI product from the US market. Despite panic selling, strong cash reserves, an active second product, and a management options grant suggest this is a regulatory setback, not a financial collapse.
HeraMED (ASX: HMD)'s Lee Health Deal: A Small Contract with a Much Bigger US Ambition
HeraMED (ASX: HMD) launched a US$317,200 commercial deployment of its HeraCARE maternity platform at Lee Health, Florida, following a successful pilot. The deal, integrated with Epic EMR, is scalable and serves as a reference case for expanding US hospital partnerships, Philips channels, and rural healthcare programs.
AML3D (ASX: AL3): Submarine Parts Order Lifts Shares Toward a Key Chart Level
AML3D (ASX: AL3) shares jumped after securing a first US Navy submarine parts order from Austal USA, building on record FY26 revenue. Trading above key support, the stock now tests a technical trigger level, with a confirmed breakout above $0.165 needed to signal further upside.
Bubs Australia (ASX: BUB): BUB's Rally Could Be Just Getting Started
Bubs Australia enters FY27 with permanent FDA approval, wider US distribution and strong American revenue growth. The company is expanding retail channels and rebuilding other markets, but higher freight costs, tariffs, negative EBITDA, and working-capital demands keep profitability and execution in focus.